Please login to the form below

Not currently logged in
Email:
Password:

nusinersen

This page shows the latest nusinersen news and features for those working in and with pharma, biotech and healthcare.

Beneluxa: the future of European market access?

Beneluxa: the future of European market access?

Spinraza (nusinersen) is the first drug approved to treat spinal muscular atrophy (SMA), an often-fatal genetic disease, which affects muscle strength and movement, and can strike in infancy or in

Latest news

More from news
Approximately 4 fully matching, plus 15 partially matching documents found.

Latest Intelligence

  • Deal Watch August 2016 Deal Watch August 2016

    95.  Ionis (US). Biogen (US). Exercise option .  Nusinersen, in phase III for treatment for spinal muscular atrophy.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Star

We're passionate about helping our clients to make a real commercial impact. We achieve this through our unique approach to...

Latest intelligence

The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...
Digital applications are transforming the market access landscape
Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....
Escaping the spin cycle of sub-optimal launch
...

Infographics